SCHEMBL30103070

SCHEMBL30103070

COc1ccc(-c2ncccc2CBr)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
KDM4E B2RXH2 5/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
CYP17A1 P05093 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 2/20 0.43
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
PDE10A Q9Y233 1/20 0.41
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MET P08581 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103148 0.89 PAX8 (0.42) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL9806866 0.81 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3782977 0.80 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL19876623 0.75 PDGFRB (0.55) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL11620358 0.74 KDM4E (0.55) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL15674480 0.74 PDGFRB (0.48) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL9806824 0.72 THRA (0.44) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL16385163 0.71 NPC1 (0.45) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3785647 0.71 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL9806780 0.71 S1PR1 (0.43) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115448913-A Bicyclic compounds for the treatment of EP2, EP4 receptor mediated diseases 武汉人福创新药物研发中心有限公司 2022-12-09 CN disclosed